| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -601,924 | -295,746 |
| Non-cash interest expense on liabilities related to revenue participation right purchase agreements | 42,306 | 27,311 |
| Stock-based compensation expense | 81,780 | 51,084 |
| Non-cash lease expense | 4,038 | 2,566 |
| Depreciation of property and equipment | 7,264 | 4,585 |
| Change in fair value of derivative liabilities | 3,300 | 2,600 |
| Change in fair value of liabilities related to rpi transactions | -13,500 | -10,700 |
| Realized gain on investment, net | 17 | 16 |
| Interest receivable and amortization on investments | -12,902 | -10,206 |
| Non-cash interest expense related to debt | 14,431 | 8,783 |
| Debt conversion expense | 121,249 | - |
| Accounts receivable | -14,842 | -8,240 |
| Prepaid and other assets | -1,264 | 5,013 |
| Accounts payable | 2,972 | -3,626 |
| Deferred revenue | -50,758 | -51,026 |
| Accrued and other liabilities | 7,235 | -382 |
| Operating lease liabilities | -6,616 | -4,466 |
| Other non-current liabilities | -2,722 | -41 |
| Net cash used in operating activities | -367,358 | -259,853 |
| Purchases of investments | 717,523 | 382,071 |
| Investment in non-marketable equity security | 5,000 | 5,000 |
| Maturities of investments | 823,551 | 549,725 |
| Sales of investments | 5,993 | 5,992 |
| Purchases of property and equipment | 19,163 | 9,809 |
| Net cash provided by (used in) investing activities | 87,858 | 158,837 |
| Repayment of finance lease liabilities | 204 | 204 |
| Repayment of term loans | 8,087 | 5,378 |
| Repayment of convertible debt | 402,500 | - |
| Proceeds from issuance of convertible debt, net | 729,460 | - |
| Proceeds from rpi transactions | 75,000 | 75,000 |
| Proceeds from issuance of common stock related to at-the-market offering, net of issuance costs-At The Market Offering | 0 | 0 |
| Proceeds from issuance of common stock related to at-the-market offering, net of issuance costs-Public Offering | 0 | 0 |
| Proceeds from issuance of common stock related to private placement, net of issuance costs | 0 | 0 |
| Proceeds from issuance of common stock under equity incentive and stock purchase plans | 21,331 | 14,396 |
| Taxes paid related to net share settlement of equity awards | 1,247 | 527 |
| Net cash provided by financing activities | 413,753 | 83,287 |
| Effect of exchange rate changes on cash | -906 | -952 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | 133,347 | -18,681 |
| Cash and cash equivalents at beginning of period | 95,232 | - |
| Cash and cash equivalents at end of period | 228,579 | - |
CYTOKINETICS INC (CYTK)
CYTOKINETICS INC (CYTK)